Biocartis Group N.V. (BIOGF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BIOGF representa a Biocartis Group N.V., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 52/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Biocartis Group N.V. (BIOGF) Resumen de Asistencia Médica y Tuberías
Biocartis Group NV specializes in molecular diagnostics with its Idylla platform, providing rapid and actionable molecular information for oncology and infectious diseases. The company partners with pharmaceutical giants like Amgen and Bristol-Myers Squibb to enhance treatment selection and monitoring, operating within the competitive medical diagnostics sector.
Tesis de Inversión
Biocartis Group NV presents a compelling investment thesis based on its innovative Idylla platform and strategic collaborations. The company's focus on rapid molecular diagnostics in oncology and infectious diseases addresses a critical need in healthcare. Key value drivers include the expansion of the Idylla platform's test menu and the growth of its installed base. The collaborations with Amgen and Bristol-Myers Squibb for biomarker testing and immuno-oncology therapies represent significant growth catalysts. However, the company's negative profit margin of -113.7% and reliance on partnerships pose potential risks. The company's market capitalization is approximately $0.07 billion. The beta of 1.39 indicates higher volatility compared to the market. Successful execution of its commercial strategy and continued innovation in diagnostic solutions are crucial for realizing the company's long-term potential.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.07 billion indicates a small-cap company with potential for growth.
- Negative P/E ratio of -0.27 reflects current unprofitability, requiring careful monitoring of future earnings.
- Gross margin of 48.2% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Profit margin of -113.7% highlights significant operational challenges and the need for improved cost management.
- Beta of 1.39 suggests higher volatility compared to the market, appealing to risk-tolerant investors.
Competidores y Pares
Fortalezas
- Innovative Idylla platform technology.
- Strategic partnerships with pharmaceutical companies.
- Rapid and accurate diagnostic results.
- Focus on oncology and infectious diseases.
Debilidades
- Negative profit margin.
- Reliance on partnerships.
- Limited geographic presence.
- Small market capitalization.
Catalizadores
- Ongoing: Expansion of the Idylla platform's test menu to include additional biomarkers and diagnostic assays.
- Ongoing: Strategic partnerships with pharmaceutical companies for companion diagnostics and biomarker testing.
- Upcoming: Potential regulatory approvals for new diagnostic tests and solutions.
- Ongoing: Geographic expansion into new markets and regions.
- Upcoming: Publication of clinical data supporting the efficacy and utility of the Idylla platform.
Riesgos
- Ongoing: Competition from larger diagnostic companies with greater resources.
- Potential: Regulatory changes and reimbursement pressures impacting the adoption of diagnostic tests.
- Potential: Technological advancements by competitors leading to obsolescence of the Idylla platform.
- Ongoing: Economic downturn and reduced healthcare spending affecting demand for diagnostic solutions.
- Potential: Dependence on key partnerships for revenue and growth.
Oportunidades de crecimiento
- Expansion of Idylla Platform Test Menu: Biocartis has the opportunity to expand its Idylla platform's test menu to include additional biomarkers and diagnostic assays. This would broaden the platform's applicability and attract a wider range of customers. The market for molecular diagnostics is expected to grow, driven by the increasing demand for personalized medicine. The timeline for expanding the test menu is ongoing, with new tests being developed and launched regularly. A competitive advantage lies in the platform's ease of use and rapid turnaround time.
- Strategic Partnerships with Pharmaceutical Companies: Biocartis can leverage its Idylla platform to establish strategic partnerships with pharmaceutical companies for companion diagnostics and biomarker testing. These partnerships can provide access to new markets and revenue streams. The market for companion diagnostics is growing rapidly, driven by the increasing use of targeted therapies. The timeline for establishing new partnerships is ongoing, with potential deals being evaluated and negotiated regularly. A competitive advantage lies in the platform's ability to provide rapid and accurate biomarker information.
- Geographic Expansion: Biocartis has the opportunity to expand its geographic presence by entering new markets and regions. This would increase the company's customer base and revenue potential. The global market for molecular diagnostics is growing, with significant opportunities in emerging markets. The timeline for geographic expansion is ongoing, with potential new markets being evaluated and targeted. A competitive advantage lies in the platform's ease of use and suitability for decentralized testing.
- Development of New Diagnostic Solutions: Biocartis can invest in the development of new diagnostic solutions and technologies to address unmet needs in healthcare. This would enhance the company's product portfolio and attract new customers. The market for innovative diagnostic solutions is growing, driven by the increasing demand for personalized medicine. The timeline for developing new solutions is ongoing, with research and development efforts focused on emerging technologies. A competitive advantage lies in the company's expertise in molecular diagnostics and its established Idylla platform.
- Focus on Infectious Disease Testing: Biocartis can capitalize on the growing demand for rapid and accurate infectious disease testing by expanding its Idylla platform's capabilities in this area. This would address a critical need in healthcare and provide a new revenue stream. The market for infectious disease testing is growing, driven by the emergence of new pathogens and the need for rapid diagnosis. The timeline for expanding infectious disease testing is ongoing, with new tests being developed and launched regularly. A competitive advantage lies in the platform's ability to provide rapid and accurate results.
Oportunidades
- Expansion of Idylla platform test menu.
- Geographic expansion into new markets.
- Development of new diagnostic solutions.
- Increasing demand for personalized medicine.
Amenazas
- Competition from larger diagnostic companies.
- Regulatory changes and reimbursement pressures.
- Technological advancements by competitors.
- Economic downturn and reduced healthcare spending.
Ventajas competitivas
- Proprietary Idylla platform technology.
- Established partnerships with pharmaceutical companies.
- Rapid and accurate diagnostic results.
- Focus on oncology and infectious diseases.
Acerca de BIOGF
Biocartis Group NV, established in 2007 and headquartered in Mechelen, Belgium, is a molecular diagnostics company focused on transforming clinical practice through innovative diagnostic solutions. The company's core offering is the Idylla platform, a real-time polymerase chain reaction (PCR) system designed to provide rapid and accurate molecular information. This platform enables clinicians to make informed treatment decisions and monitor treatment progress, particularly in oncology. Biocartis offers a range of tests for the Idylla platform, including assays for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutations, which are critical biomarkers in cancer. Additionally, the company provides tests for infectious diseases, such as the Idylla SARS-CoV-2/Flu/RSV panel and SARS-CoV-2 tests, as well as the SeptiCyte RAPID test for rapid host-response assessment. Biocartis collaborates with pharmaceutical companies like Amgen and Bristol-Myers Squibb to develop and commercialize diagnostic tests for targeted therapies. These partnerships leverage the Idylla platform's capabilities to accelerate access to biomarker information and improve patient outcomes. The company also provides research products, including various mutation assays for research purposes. Biocartis aims to enhance clinical practice by providing rapid, accurate, and actionable molecular information, benefiting patients, clinicians, payers, and the healthcare industry as a whole.
Qué hacen
- Develops and commercializes the Idylla platform for rapid molecular diagnostics.
- Offers a range of diagnostic tests for oncology, including BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests.
- Provides tests for infectious diseases, such as SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests.
- Offers the SeptiCyte RAPID test for rapid host-response assessment.
- Provides research products, including various mutation assays for research purposes.
- Collaborates with pharmaceutical companies to develop and commercialize diagnostic tests for targeted therapies.
- Focuses on enhancing clinical practice by providing rapid, accurate, and actionable molecular information.
Modelo de Negocio
- Sales of Idylla platform instruments and consumables.
- Revenue from diagnostic tests for oncology and infectious diseases.
- Partnerships with pharmaceutical companies for companion diagnostics and biomarker testing.
- Sales of research products, including mutation assays.
Contexto de la Industria
Biocartis Group NV operates in the rapidly evolving medical diagnostics and research industry. The market is driven by increasing demand for personalized medicine, advancements in molecular diagnostics, and the need for rapid and accurate diagnostic solutions. The competitive landscape includes companies like EEOIF, GDNSF, HRPMF, KDEVF, and KIARF, as well as larger players in the diagnostics market. Biocartis differentiates itself through its Idylla platform, which offers rapid and easy-to-use molecular testing. The industry is expected to continue growing, driven by technological advancements and increasing healthcare expenditure. Biocartis's success depends on its ability to innovate, expand its test menu, and establish strategic partnerships.
Clientes Clave
- Hospitals and clinical laboratories.
- Pharmaceutical companies.
- Research institutions.
- Healthcare providers.
Finanzas
Gráfico e información
Precio de la acción de Biocartis Group N.V. (BIOGF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BIOGF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BIOGF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BIOGF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BIOGF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Roger Moody
CEO
Roger Moody serves as the CEO of Biocartis Group NV, leading the company's strategic direction and operations. His background includes extensive experience in the healthcare and diagnostics industries. Prior to joining Biocartis, Moody held leadership positions at various multinational corporations, where he focused on driving growth and innovation. His expertise spans across commercial operations, product development, and market access. Moody's leadership is instrumental in guiding Biocartis through its next phase of expansion and development.
Historial: Under Roger Moody's leadership, Biocartis has focused on expanding its Idylla platform's test menu and strengthening its partnerships with pharmaceutical companies. Key achievements include the development and launch of new diagnostic tests and the expansion of the company's geographic presence. Moody has also overseen the implementation of strategic initiatives to improve operational efficiency and drive revenue growth. His focus on innovation and collaboration has positioned Biocartis for long-term success in the competitive molecular diagnostics market.
Información del mercado OTC de BIOGF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biocartis Group NV may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is typically associated with higher risk due to the potential for less transparency and liquidity compared to higher-tiered OTC stocks or exchange-listed stocks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Potential for lower trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and market potential.
- Review the company's legal and regulatory compliance.
- Monitor the company's news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Established partnerships with reputable pharmaceutical companies like Amgen and Bristol-Myers Squibb.
- Proprietary Idylla platform technology with a focus on molecular diagnostics.
- Focus on oncology and infectious diseases, addressing critical healthcare needs.
- Presence of a CEO with experience in the healthcare and diagnostics industries.
Lo Que los Inversores Preguntan Sobre Biocartis Group N.V. (BIOGF)
¿Cuáles son los factores clave para evaluar BIOGF?
Biocartis Group N.V. (BIOGF) actualmente tiene una puntuación IA de 52/100, indicando puntuación moderada. Fortaleza clave: Innovative Idylla platform technology.. Riesgo principal a monitorear: Ongoing: Competition from larger diagnostic companies with greater resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BIOGF?
BIOGF actualmente puntúa 52/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BIOGF?
Los precios de BIOGF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BIOGF?
La cobertura de analistas para BIOGF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BIOGF?
Las categorías de riesgo para BIOGF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Competition from larger diagnostic companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BIOGF?
La relación P/E para BIOGF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BIOGF sobrevalorada o infravalorada?
Determinar si Biocartis Group N.V. (BIOGF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BIOGF?
Biocartis Group N.V. (BIOGF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide additional insights.